<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="928">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835314</url>
  </required_header>
  <id_info>
    <org_study_id>12-0315</org_study_id>
    <nct_id>NCT01835314</nct_id>
  </id_info>
  <brief_title>Compassionate Use of Stiripentol in Dravet Syndrome</brief_title>
  <official_title>Compassionate Use of Stiripentol in Dravet Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compassionate use of Stiripentol in Dravet Syndrome. This is a treatment protocol, not a
      research study, therefore children will only be monitored on a clinical basis for seizure
      improvement predominantly by parent and caregiver report.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a treatment protocol for compassionate use, not a research study, therefore children
      will only be monitored on a clinical basis for seizure improvement predominantly by parent
      and caregiver report.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Dravet Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stiripentol</intervention_name>
    <description>Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Children with genetic confirmation of Dravet syndrome (a documented sodium channel,
        voltage-gated, type I, alpha subunit (SCN1A) mutation) or clinical confirmation of Dravet
        syndrome by two pediatric neurologist will be considered to have Dravet syndrome. In order
        to enter the treatment protocol there will be documented treatment failure of at least two
        therapeutic anticonvulsants excluding Na channel blockers. Anticonvulsants that are Na
        channel blockers such as carbamazepine and lamotrigine as known to provoke seizures in
        this patient population.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Kelly Knupp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado/Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Knupp, MD</last_name>
    <phone>720-777-6895</phone>
    <email>kelly.knupp@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia M Camuto, BA</last_name>
    <phone>720-777-5514</phone>
    <email>alicia.camuto@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kelly Knupp, MD</last_name>
      <phone>720-777-6895</phone>
      <email>kelly.knupp@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Alicia Camuto, BA</last_name>
      <phone>720-777-5514</phone>
      <email>alicia.camuto@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kelly Knupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 8, 2015</lastchanged_date>
  <firstreceived_date>April 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stiripentol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
